slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 481-510
Pages 1,064
Rows per page 30
Loop
481-510 of 31,900
21
Hospital Priorities 2022 China Edition: Strategic Implications for Pharma CompaniesHospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
22
Data from L.E.K. 2021, 2022 APAC Hospital Priorities Survey.Hospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
23
The slide uses a stacked bar chart to visualize survey data regarding hospital access restrictions for pharmaceutical sales representatives.Hospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
24
The slide combines survey data on digital tool acceptance with epidemiological data on COVID-19 cases to justify the shift toward digital engagement.Hospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
25
Survey data from 120 respondents in 2021 and 2022.Hospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
26
Data based on a survey of 120 respondents.Hospital Priorities 2022 China Edition: Strategic Implications for Pharma Companies · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
04
Impact of the US BIOSECURE Act on Biopharmas, Contract Services and InvestorsImpact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
05
Impact of the US BIOSECURE Act on Biopharmas, Contract Services and InvestorsImpact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
06
The chart uses a grouped bar format to compare 'Before' and 'After' confidence scores (0-10 scale) with percentage change annotations.Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
07
The chart uses a multi-select survey format, so percentages may not sum to 100%.Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
08
The chart uses a custom layout with a central axis and directional arrows to indicate sentiment/impact.Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
09
The chart displays multi-select survey data.Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
The chart displays survey results regarding the impact of the US BIOSECURE Act on partnering intentions.Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
33
The chart uses a grouped bar format to compare two segments (Public vs Private hospitals) across 8 categories of concerns.Japan Hospital Insights Survey Findings Summary materials · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
34
The 2x2 matrix positions L.E.K. at the intersection of 'Strategic Perspectives' and 'Research Emphasis'.Japan Hospital Insights Survey Findings Summary materials · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
15
The slide uses a 'problem-solution' structure, acknowledging the challenges at the top and noting progress in the bottom text.L.E.K. ASC Insights Study MedTech Publication Deck · L.E.K.
Consulting deck Strategy consulting Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
16
The slide uses a three-pillar structure to categorize strategic questions.L.E.K. ASC Insights Study MedTech Publication Deck · L.E.K.
Consulting deck Strategy consulting Beat · ActionLoop · Cost Of Inaction1 hit
10
The slide uses two horizontal bar charts to contrast partnership drivers with operational pain points.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a green color palette consistent with L.E.K. branding. The content is structured as a list of failure modes.L.E.K.’s 2024 ASC Insights Study Key takeaways for provider organizations · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
07
The slide uses a side-by-side comparison framework to contrast opposing economic forces.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
09
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
10
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
12
The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
13
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
16
The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit